Skip to main content
Journal of Ophthalmic Inflammation and Infection logoLink to Journal of Ophthalmic Inflammation and Infection
. 2026 Aug 8;16:68. doi: 10.1186/s12348-026-00629-3

Period prevalence of ocular inflammation and corneal allograft rejection within 30 days of COVID-19 vaccination

Sadegh Ghafarian 1,#, Sarah Pajek 2,#, Ruiyang Huang 2, Mona A El Gendi 2, Jane Nguyen 2, Ann Pham 2, Andrea C Santiago-Leon 2, Ellen H Koo 2,✉
PMCID: PMC13740413  PMID: 42988971

Abstract

Purpose

To determine the period prevalence of new or recurrent ocular inflammation, including corneal allograft rejection, occurring within 30 days after COVID-19 vaccination.

Methods

This retrospective cohort study was conducted at a tertiary referral eye center. A systematic random sample of 4,638 patient charts (50% of eligible charts after removal of duplicate encounters identified by relevant ICD-10 codes) from December 1, 2020, to April 9, 2023, was reviewed using a computer-generated random start and a fixed sampling interval of 2. Patients were included if they developed new or recurrent ocular inflammation within 30 days of COVID-19 vaccination. Main outcome measures included the period prevalence of post-vaccination ocular inflammation, the proportion with new-onset inflammation, the proportion with recurrent inflammation among patients with prior inflammatory disease, and the frequency of corneal allograft rejection.

Results

Among the 4,638 sampled patients with ocular inflammation-related ICD-10 codes, 77 met inclusion criteria, representing a period prevalence of 1.66% within 30 days of COVID-19 vaccination. The mean age was 58.0 years and 58.4% were male. Diagnoses included uveitis (n = 38), herpetic keratitis (n = 32), birdshot choroidopathy (n = 2), chorioretinitis (n = 2), pars planitis (n = 1), Staphylococcus-associated marginal keratitis (n = 1), and corneal allograft rejection (n = 1). Among patients with prior ocular inflammation, 0.65% experienced a recurrent event within 30 days of vaccination; among those without prior history, 1.01% had newly documented inflammation in the same window. The single episode of corneal allograft rejection occurred 13 days after the second dose of the Pfizer-BioNTech vaccine in a patient with prior Descemet stripping endothelial keratoplasty for Fuchs corneal dystrophy. Most cases responded to corticosteroid or antiviral therapy.

Conclusion

Ocular inflammation within 30 days of COVID-19 vaccination was uncommon, and corneal allograft rejection was exceptionally rare in this large tertiary-center cohort. These findings support the continued use of COVID-19 vaccination in patients with prior ocular inflammatory disease or corneal transplantation, with appropriate post-vaccination monitoring.

Keywords: COVID-19 vaccination, Ocular inflammation, Period prevalence, Uveitis, Herpetic keratitis, Corneal allograft rejection, Recurrence rate, Incidence

Key Message

What is known

• Sporadic cases of ocular inflammation, including uveitis, herpetic keratitis, and rare corneal allograft rejection, have been reported following COVID-19 vaccination, raising concern among patients with prior inflammatory eye disease or corneal transplantation.

New information from this study

• In a large tertiary-center cohort, ocular inflammation occurring within 30 days of COVID-19 vaccination was uncommon, with a low period prevalence of 1.66%.

• Both recurrence of pre-existing ocular inflammatory disease (0.65%) and new-onset ocular inflammation (1.01%) after vaccination were rare and generally responsive to standard medical therapy.

• Corneal allograft rejection following COVID-19 vaccination was exceptionally rare, with only a single documented case identified in this cohort.

Introduction

During the global COVID-19 pandemic, the rapid development of vaccines based on novel mRNA technology offered an effective strategy for pandemic control, while simultaneously raising public concerns regarding potential adverse effects and long-term safety [1, 2]. As with other vaccines, SARS-CoV-2 vaccination of patients with transplants or with underlying autoimmune or inflammatory conditions had to be weighed against the risk of both post-vaccine inflammation and the risk of inflammation from COVID-19 itself. This included vaccinating patients with a history of uveitis, viral keratitis, or those who had received a corneal allograft transplant. Several case reports described ocular inflammation in such patients after SARS-CoV-2 vaccination [3–5].

Effective vaccinations include an intentional immune response for the development of new memory cells. For a variety of vaccines, this inflammatory response has been reported to cause unintentional ocular inflammation as well [6–8]. Although these ocular inflammatory events appear to be uncommon, they may be of particular concern in patients at increased risk of corneal allograft rejection or uveitis recurrence [3, 9].

In this descriptive population study, we examine the period prevalence of ocular inflammation and corneal allograft rejection occurring in patients who received the SARS-CoV-2 vaccination.

Methods

This was a retrospective chart review using existing clinical data. The requirement for informed consent was waived by the University of Miami Institutional Review Board, as the study involved no prospective patient contact or intervention and posed minimal risk to participants. The study was approved by the University of Miami Institutional Review Board, was conducted in accordance with the principles of the Declaration of Helsinki, and was compliant with the Health Insurance Portability and Accountability Act. A retrospective chart review was conducted at the Bascom Palmer Eye Institute for the period from December 1, 2020, to April 9, 2023. During this interval, a total of 9,276 unique charts met the initial eligibility criteria on data extraction based on relevant ICD-10 diagnostic codes, after removal of duplicate patient encounters. Given the volume of records, full review of all eligible charts was not feasible; systematic random sampling was therefore used to select 50% of eligible charts for detailed review, yielding a final sample of 4,638 patients. A computer-generated random number was used to select the initial record, and every other chart was then selected (sampling interval = 2), giving each eligible patient an equal probability of inclusion. The eligible dataset was reviewed in the default order returned by the data extraction system, without sorting by date, provider, or diagnostic code (Fig. 1).

Fig. 1.

Fig. 1

Flowchart of patient selection

The included ICD-10 codes encompassed herpes simplex virus (HSV) keratitis (B00.52), varicella zoster virus (VZV) keratitis (B01.81), herpes zoster ophthalmicus (B02.30), keratitis (H16), iridocyclitis (H20), chorioretinal inflammation (H30), chorioretinal disorders in diseases classified elsewhere (H32), disorders of the globe (H44), and complications of corneal transplantation (T86.84).

Patients aged 18 years or older were included if they were newly diagnosed or had a reactivation of uveitis, infectious keratitis, or corneal allograft rejection in the immediate post-vaccination period, defined as within 30 days after COVID-19 vaccination. Patients were excluded if the ocular inflammatory event began prior to COVID-19 vaccination, occurred more than 30 days after vaccination, if an immunosuppressive medication had been discontinued at the prior visit, or if ocular surgery or trauma had occurred within the preceding 30 days. Ultimately, 77 patients met the criteria and were included in the final analysis (Fig. 1). Additional data for these patients was recorded, including demographics, smoking status, autoimmune diagnoses, cancer diagnoses, ocular comorbidities, vaccine brand, treatment plan and days to inflammation resolution. Resolution was defined on the basis of clinician documentation of symptomatic and clinical resolution at follow-up, including absence of ciliary injection, active anterior chamber cells, keratic precipitates (KPs), and corneal edema where applicable based on the presenting diagnosis. Time to resolution was calculated from the date of diagnosis. Patients lost to follow-up were excluded from resolution analyses.

Data analysis

Patients with new ocular inflammation were analyzed as two separate subgroups: those with history of ocular inflammation that was quiescent prior to vaccination (“Flare”) and those with no prior known history of ocular inflammation (“New”) (Fig. 1). Corneal allograft rejection was analyzed in the Flare subgroup. Data was analyzed using SPSS Statistics, Version 25.0 software (IBM Corp., Armonk, NY, USA). Figures and tables were created using Microsoft Excel version 16.61.1.

Results

Among the 4,638 sampled patients with ocular inflammation-related ICD-10 codes, 77 (1.66%) had ocular inflammation documented within 30 days of COVID-19 vaccination. The mean age was 57.64 years (SD, 16.12; range, 18–89 years), and 45 patients (58.4%) were male. (Table 1). Age was similar for both subgroups, but the new subgroup had a higher proportion of male patients (32/47, 68.1%). Most patients were White (66/77, 85.7%), with about half of these being White Hispanic (36/77, 46.8%). Most patients also identified as “never smokers” (52/77,67.5%) and 16 (20.8%) had a history of diabetes mellitus (Table 1).

Table 1.

Demographics

Overall Flare subgroup New subgroup
N (%) 77 (100%) 30 (38.96%) 47 (61.04%)
Age (years) 57.64 (SD: 16.12) 56.84 (SD: 18.67) 58.15 (SD: 14.45)
Sex

45 male (58.44%)

33 female (42.86%)

13 male (43.33%)

17 female (56.67%)

32 male (68.09%)

16 female (34.04%)

Race

66 White (85.71%)

7 Black (9.091%)

3 Asian (3.896%)

1 unknown (1.299%)

24 White (80.00%)

4 Black (13.33%)

1 Asian (3.33%)

1 unknown (3.33%)

42 White (89.36%)

3 Black (6.383%)

2 Asian (4.255%)

Ethnicity 36 Hispanic (46.75%) 12 Hispanic (40.00%) 24 Hispanic (51.06%)
Smoking status

4 current (5.195%)

21 former (27.27%)

52 never (67.53%)

1 current (3.33%)

9 former (30.00%)

20 never (66.67%)

3 current (6.383%)

12 former (25.53%)

32 never (68.09%)

Diabetes 16 (20.78%) 5 (16.67%) 11 (23.40%)
At least one ocular Comorbidities 35 (45.5%) 21 (70.00%) 14 (29.8%)
Medical condition affecting immune status 24 (31.37%) 17 (56.67%) 7 (14.89%)

A total of 35 patients (45.5%) had at least one chronic ocular comorbidity, including 21 patients (70.0%) in the Flare subgroup and 14 patients (29.8%) in the New subgroup (Table 1). In the Flare subgroup, ocular comorbidities included glaucoma in 12 patients (40.0%), cystoid macular edema in 4 (13.3%), Fuchs corneal dystrophy in 3 (10.0%), historical retinal detachment in 2 (6.7%), non-proliferative diabetic retinopathy in 2 (6.7%), corneal edema in 2 (6.7%), macular degeneration in 1 (3.3%), retinal vasculitis in 1 (3.3%), and non-arteritic anterior ischemic optic neuropathy (NAION) in 1 (3.3%). In the New subgroup, ocular comorbidities included glaucoma in 8 patients (17.0%), non-proliferative diabetic retinopathy in 4 (8.5%), cystoid macular edema in 3 (6.4%), macular degeneration in 1 (2.1%) and keratoconus in 1 (2.1%).

Regarding medical conditions affecting the immune system, 24 patients (31.4%) had such conditions, including 17 (56.7%) in the Flare subgroup and 7 (14.9%) in the New subgroup (Table 1). In the Flare subgroup, immunocompromising conditions included rheumatoid arthritis in 6 patients (20.0%), birdshot choroidopathy in 2 (6.7%), ankylosing spondylitis in 2 (6.7%), multiple sclerosis in 1 (3.3%), Vogt-Koyanagi-Harad in 1 (3.3%), dermatomyositis in 1 (3.3%), Hashimoto’s thyroiditis in 1 (3.3%), discoid lupus in 1 (3.3%), recent postpartum status in 1 (3.3%), Waldenström macroglobulinemia in 1 (3.3%). Of these, 10 (33.3%) were taking immunosuppressant medications and 5 were HLA-B27 positive (16.7%). In the New subgroup, immunocompromising conditions included psoriasis in 2 patients (4.3%), concurrent use of oral prednisone in 2 (4.3%), ankylosing spondylitis in 1 (2.1%), uveal melanoma undergoing treatment in 1 (2.1%), and metastatic lung adenocarcinoma undergoing chemotherapy in 1 (2.1%).

Of 77 (1.66%) who had ocular inflammation documented within 30 days of COVID-19 vaccination, 30 (39.0%) occurred in patients with a distant history of ocular inflammation or corneal allograft transplantation, representing 0.65% of the sampled cohort (Table 2). 19 (63.3%) were cases of recurrent uveitis, including 12 (15.6%) cases of anterior uveitis, 3 (3.9%) of intermediate uveitis, 2 (2.6%) of posterior uveitis, and 2 (2.6%) of panuveitis. 7 (23.3%) were viral, including 4 (5.2%) related to VZV and 3 (3.9%) to HSV. Other flare cases included 2 (2.6%) of birdshot choroidopathy and 1 (1.3%) of Staphylococcus-associated marginal keratitis. There was also 1 (1.3%) case of corneal allograft rejection. 47 (61.0%) cases occurred in patients without prior history of ocular inflammation, representing 1.01% of the sampled cohort (Table 2). This included 22 (28.6%) cases of anterior uveitis, 16 (20.8%) cases related to HSV, and 9 (11.7%) cases related to VZV.

Table 2.

Cumulative incidence by subgroup

Total
n (%)
Cumulative incidence
All 77 (100%) 1.66%
Flare subgroup 30 (38.96%) 0.65%
Anterior uveitis 12 (15.58%) 0.26%
Intermediate uveitis 3 (3.896%) 0.06%
Posterior uveitis 2 (2.597%) 0.04%
Panuveitis 2 (2.597%) 0.04%
VZV-related 4 (5.195%) 0.09%
HSV-related 3 (3.896%) 0.06%
Birdshot choroidopathy 2 (2.597%) 0.04%

Staphylococcus-

associated marginal keratitis

1 (1.299%) 0.02%
Corneal allograft rejection 1 (1.299%) 0.02%
New subgroup 47 (61.04%) 1.01%
Anterior uveitis 22 (28.57%) 0.47%
HSV-related 16 (20.78%) 0.34%
VZV-related 9 (11.69%) 0.19%

The timing of ocular inflammatory events following COVID-19 vaccination was as follows: most cases (45, 58.4%) occurred after the first dose (15 [50.0%] in the Flare subgroup, 30 [63.8%] in the New subgroup; Table 3), 26 cases (33.8%) occurred after the second dose (10 [33.3%] Flare, 16 [34.0%] New), and 6 cases (7.8%) occurred after the third dose (5 [16.7%] Flare, 1 [2.1%] New). Vaccine brands received prior to the ocular inflammation diagnosis included 53 (68.8%) Pfizer-BioNTech, 21 (27.3%) Moderna, and 3 (3.9%) Johnson & Johnson (Table 4). Mean time from vaccination to diagnosis was 14.49 (SD: 8.632) days (Table 5). All patients achieved symptom resolution except the 1 corneal allograft rejection case (1.3%). Time to symptom resolution was 59.17 (SD: 49.44) days for the Flare subgroup and 26.68 (SD: 29.95) days for the New subgroup (Table 5). Patients who were lost to follow-up were excluded from resolution analysis: 5 (16.7%) in the Flare subgroup and 7 (14.9%) in the New subgroup.

Table 3.

Related vaccine dose by diagnosis

Dose 1
n (%)
Dose 2
n (%)
Dose 3
n (%)
All 45 (58.44%) 26 (33.77%) 6 (7.79%)
Flare subgroup 15 (50.00%) 10 (33.33%) 5 (16.67%)
Anterior uveitis 5 (41.67%) 6 (50.00%) 1 (8.333%)
Intermediate uveitis 1 (33.33%) 2 (66.67%) -
Posterior uveitis 1 (50.00%) - 1 (50.00%)
Panuveitis 1 (50.00%) - 1 (50.00%)
VZV-related 4 (100%) - -
HSV-related 2 (66.67%) - 1 (33.33%)
Birdshot choroidopathy 1 (50.00%) - 1 (50.00%)

Staphylococcus-

associated

marginal keratitis

- 1 (100%) -
Corneal allograft rejection - 1 (100%) -
New subgroup 30 (63.83%) 16 (34.05%) 1 (2.128%)
Anterior uveitis 17 (77.27%) 5 (10.64%)
HSV-related 11 (68.75%) 4 (25.00%) 1 (6.250%)
VZV-related 2 (22.22%) 7 (77.78%)

Table 4.

Related vaccine brand by diagnosis

Pfizer
n (%)
Moderna
n (%)
Johnson & Johnson
n (%)
All 53 (68.83%) 21 (27.27%) 3 (3.90%)
Flare subgroup 22 (73.33%) 8 (26.67%) -
Anterior uveitis 9 (75.00%) 3 (25.00%) -
Intermediate uveitis 2 (66.67%) 1 (33.33%) -
Posterior uveitis 1 (50.00%) 1 (50.00%) -
Panuveitis 2 (100%) - -
VZV-related 2 (50.00%) 2 (50.00%) -
HSV-related 2 (66.67%) 1(33.33%) -
Birdshot choroidopathy 2 (100%) - -

Staphylococcus-

associated

marginal keratitis

1 (100%) - -
Corneal allograft rejection 1 (100%) - -
New subgroup 31 (65.96%) 13 (27.66%) 3 (6.383%)
Anterior uveitis 16 (72.73%) 4 (18.18%) 2 (9.091%)
HSV-related 9 (56.25%) 7 (43.75%) -
VZV-related 6 (66.67%) 2 (22.22%) 1 (11.11%)

Table 5.

Days to diagnosis and to clinical resolution

Mean interval from vaccine to diagnosis (days) Mean time to resolution (days)
All 14.49 (SD: 8.632) 38.86 (SD: 41.22)*
Flare subgroup 13.6 (SD: 9.137) 59.17 (SD: 49.44)*
Anterior uveitis 12.67 (SD: 9.306) 61.00 (SD: 48.46)*
Intermediate uveitis 7.67 (SD: 5.03) 108.50 (SD: 27.58)*
Posterior uveitis 15.50 (SD: 2.12) 40.00 (SD: 14.14)
Panuveitis 21.00 (SD: 12.73) 93.00 (SD: 93.34)
VZV-related 16.25 (SD: 13.55) 52.75 (SD: 54.84)
HSV-related 14.33 (SD: 11.02) 2*
Birdshot choroidopathy 11.50 (SD: 13.44) 43*

Staphylococcus-

associated

marginal keratitis

16 10
Corneal allograft rejection 13 not applicable
New subgroup 15.06 (SD: 8.34) 26.68 (SD: 29.95)*
Anterior uveitis 13.95 (SD: 8.88) 25.26 (SD: 29.65)*
HSV-related 15.19 (SD: 7.90) 25.13 (SD: 32.27)*
VZV-related 17.56 (SD: 8.11) 35.00 (SD: 28.57)*

*Excludes patients that were lost to follow up

Treatment of uveitis in the Flare subgroup included ophthalmic prednisolone acetate 1% for 15 patients (79.0%), ophthalmic cyclopentolate for 5 (26.3%), oral prednisone for 2 (10.5%), ophthalmic difluprednate 0.05% for 2 (10.5%), and ophthalmic dexamethasone/neomycin/polymyxin for 1 (5.3%). In the New subgroup, uveitis treatments included ophthalmic prednisolone acetate 1% for 22 patients (100%), ophthalmic cyclopentolate for 12 (54.5%), oral valacyclovir for 4 (18.2%), ophthalmic atropine for 3 (13.6%), and ophthalmic ketorolac tromethamine for 1 (4.5%).

In the Flare subgroup, all patients with viral diagnoses (HSV and VZV keratitis and keratouveitis, consistent with the ICD-10 codes used for patient identification) were treated with oral valacyclovir, with adjunctive topical corticosteroids used in 5 patients (71.4%). In the New subgroup, oral valacyclovir was used in 24 patients (96.0%), with additional therapies including topical corticosteroids (36.0%), cycloplegics (24.0%), and topical antivirals (16.0%). One patient receiving concurrent chemotherapy required intravenous foscarnet and ganciclovir.

Of the 2 Flare cases of birdshot choroidopathy, 1 (50.0%) did not receive additional treatment and 1 (50.0%) received a dexamethasone implant. The case of Staphylococcus-associated marginal keratitis in the Flare subgroup was treated with oral doxycycline, ophthalmic polymyxin B sulfate/trimethoprim, and ophthalmic fluorometholone.

The case of corneal graft rejection was diagnosed 13 days after the patient’s second dose of Pfizer-BioNTech COVID-19 vaccination (Tables 3 and 4). It occurred 570 days after the initial descemet’s stripping endothelial keratoplasty (DSEK) procedure for the treatment of Fuchs corneal dystrophy. The rejection was treated with prednisolone without improvement and subsequent allograft transplantation was required.

Discussion

More than five years after the COVID-19 pandemic, which has resulted in hundreds of millions of confirmed infections and millions of deaths worldwide [10], there is now sufficient clinical experience to critically evaluate not only the effectiveness of vaccination strategies but also their potential short- and intermediate-term complications.

Uveitis is among the most commonly reported ophthalmic adverse events following COVID-19 vaccination, with more than 70 published case reports and case series to date [11, 12]. Consequently, patients with a history of uveitis, keratoplasty, or other immune-mediated ocular conditions may be particularly concerned about post-vaccination inflammation, although evidence linking COVID-19 vaccination to an increased risk of uveitis flare remains controversial [1, 13–16]. A large analysis of vaccine adverse event reports identified 1,094 cases of vaccine-associated uveitis from 40 countries, demonstrating a low crude reporting rate and suggesting a possible temporal association between reported uveitis events and COVID-19 vaccination, without evidence of a significant safety signal [4].

In the current study, the period prevalence of ocular inflammation occurring within 30 days of COVID-19 vaccination was 1.66% among patients with ocular inflammation-related ICD-10 codes, indicating that such events are very uncommon. However, this figure does not represent the incidence or prevalence of post-vaccination ocular inflammation in the broader vaccinated population. Because the denominator was restricted to patients with inflammatory diagnoses at a tertiary referral center, the proportion of all vaccinated individuals who develop such events is likely considerably lower. Importantly, a temporal association between vaccination and an inflammatory event does not necessarily establish causality [12, 16]. Recurrent uveitis occurred in 19 of 4,638 patients (0.41%), which is higher than the estimated recurrence rate in the general population of approximately 0.02–0.05% per year [17–19]; however, this difference likely reflects the enrichment of patients with pre-existing ocular inflammatory disease in the study cohort rather than a causal effect of vaccination.

The pathogenesis of uveitis following COVID-19 vaccination remains incompletely understood and is likely multifactorial. Proposed mechanisms include molecular mimicry between vaccine antigens and uveal self-peptides, delayed-type hypersensitivity reactions, and immune responses directed against vaccine adjuvants, all of which may disrupt ocular immune privilege [16, 20].

Vaccination-induced increases in vascular permeability may further facilitate immune complex deposition within the uvea and iris, triggering localized inflammation [21]. mRNA vaccines may contribute to ocular inflammation through several immunological mechanisms. Certain vaccine components, such as polyethylene glycol used in mRNA delivery systems, can activate complement pathways [22–24], while the mRNA platform itself stimulates innate immunity via endosomal and cytoplasmic nucleic acid receptors, resulting in activation of proinflammatory signaling cascades that may be amplified in individuals with underlying autoimmune susceptibility [25–27]. In addition, the RNA component may directly activate type I interferon responses, potentially inducing retinal pigment epithelium cell injury and providing an additional mechanistic pathway for post-vaccination ocular inflammation [28–30].

The second most common conditions observed in our study were viral manifestations (HSV and VZV), affecting 7 patients (9.1%) in the Flare subgroup and 25 patients (16.1%) in the New subgroup. The recurrence rates for HSV and VZV were 0.4% and 0.3%, respectively, which exceed the reported recurrence rate of HSV keratitis in the USA, estimated at 15.6 per 100,000 person-years [31]. Previous studies have indicated that both new onset and recurrent HSV keratitis may be more likely following COVID-19 vaccination [32, 33]. An earlier report on infectious keratitis post-COVID-19 vaccination documented a mean interval of 12.3 ± 10.3 days between vaccination and symptom onset [34], comparable to the interval observed in our cohort. Vaccines are hypothesized to trigger viral reactivation via T-cell-mediated immune activation and upregulation of proinflammatory cytokines [35]. The cases presented here are consistent with prior reports, suggesting that COVID-19 vaccination may be temporally associated with herpesvirus reactivation even after prolonged periods of quiescence [36, 37]. Accordingly, prophylactic antiviral therapy may be considered in selected patients with a history of herpetic keratitis who are deemed to be at high risk of recurrence following vaccination [38].

In addition, we report the second known case of post-vaccination Staphylococcus-associated marginal keratitis [39]. This case involved a 60-year-old female who experienced recurrence 16 days after her second dose of the Pfizer-BioNTech vaccine and achieved symptom resolution within 10 days following appropriate treatment. We also identified two cases of birdshot choroidopathy exacerbation after vaccination, both occurring in females in their 80s. One patient achieved symptom resolution in 43 days, while the other was lost to follow-up. To our knowledge, only one prior case has been reported, a 54-year-old female who developed exacerbation six weeks after receiving the Sputnik COVID-19 vaccine, with no reported time to resolution [40].

In this cohort, most post-vaccination inflammatory events occurred following mRNA-based vaccines (Pfizer-BioNTech and Moderna), with relatively few cases observed after the Johnson & Johnson vaccine. These distributions are consistent with prior reports and likely reflect the predominant use of mRNA vaccines during the study period [4]. Inflammatory events were most frequently observed after the first vaccine dose, with fewer cases after the second and only a small proportion after subsequent doses. These dose distributions are consistent with two large population-based studies reporting a higher frequency of inflammatory events after the initial vaccine dose [4, 41]. However, some reports have described a higher frequency of uveitis following the second or subsequent doses of COVID-19 vaccination, underscoring variability in mechanism and individual immune responses [16, 27, 42]. The time to uveitis diagnosis after COVID-19 vaccination has previously been reported to average 8.0 ± 8.6 days after vaccination [11]. In our cohort, the time to diagnosis varied by uveitis subtype, with the earliest onset observed in intermediate uveitis flares (7.67 ± 5.03 days) and the latest onset in panuveitis (21.00 ± 12.73 days) (Table 5).

Given reports of corneal allograft rejection occurring within several weeks of COVID-19 vaccination, it is important to assess whether vaccination may be associated with an increased risk of graft rejection [43–45]. An analysis of the Centers for Disease Control(CDC) Vaccine Adverse Event Reporting(VAER) System identified 46 patients (55 eyes) with reported corneal graft rejection following COVID-19 vaccination, predominantly after mRNA vaccines, and suggested a possible temporal association, with earlier onset observed after the second vaccine dose and in patients with a history of endothelial keratoplasty [46]. In our cohort, only a single case of corneal allograft rejection was identified. The patient was a 67-year-old woman who had undergone Descemet stripping endothelial keratoplasty (DSEK) for Fuchs corneal dystrophy 570 days prior to presentation, with rejection occurring 13 days after the second dose of the Pfizer-BioNTech vaccine. Despite treatment with topical prednisolone acetate 1%, the rejection did not resolve and ultimately required repeat keratoplasty. Accordingly, cornea specialists should closely monitor patients with a history of keratoplasty after COVID-19 vaccination and counsel them to promptly report symptoms such as photophobia, ocular pain, or reduced vision.

In our study, most patients with uveitis responded favorably to corticosteroid therapy, with 98.7% achieving symptom resolution over a mean duration of 38.86 ± 41.22 days, a response pattern consistent with an immune-mediated mechanism underlying post-vaccination uveitis. Beyond their therapeutic role, concomitant use of systemic glucocorticoids at the time of COVID-19 vaccination has been associated with a dose-dependent reduction in the risk of post-vaccination uveitis relapse [16, 47]. In the setting of post-vaccination corneal allograft rejection, early initiation of topical corticosteroid therapy has been reported to achieve complete reversal of rejection episodes [43]. Importantly, short-term corticosteroid use in the peri-vaccination period has been shown to be safe, reducing vaccine-related inflammatory adverse effects without impairing vaccine-elicited serologic antibody responses [48].

In the current study, inflammatory events following COVID-19 vaccination were rare and responded favorably to standard medical therapy. These findings should be interpreted in the context of the risks associated with COVID-19 infection itself. SARS-CoV-2 infection can result in a range of systemic and ocular manifestations [49, 50] and has been shown to significantly increase the risk of uveitis recurrence, whereas this risk appears to be reduced in individuals who contract COVID-19 after prior vaccination [51]. SARS-CoV-2 proteins have been detected in tear samples up to three months after the initial infection in reported cases of post-infectious viral keratouveitis [52], and viral RNA has also been demonstrated in the aqueous humor of asymptomatic individuals. These findings raise the possibility that SARS-CoV-2 may persist within immunoprivileged ocular compartments after the acute phase of infection [53], underscoring the importance of preventing infection in the first place.

This study has several limitations. First, its retrospective design and reliance on chart review introduce potential inaccuracies and incomplete documentation. Reliance on self-reported vaccination history in some cases could introduce recall bias, and that the precise proportion of cases verified exclusively by patient report could not be determined from the available retrospective data. However, where possible, vaccine date, brand, and dose number were verified through documented clinical records.

Second, because patients were identified using ICD-10 codes for ocular inflammation, the denominator represents an enriched inflammatory cohort rather than all vaccinated individuals; therefore, the calculated proportions do not reflect population-level incidence and this study does not assess vaccine safety at the population level. Third, the date of diagnosis may not precisely correspond to the true onset of inflammation or graft rejection, and in some cases, symptoms may have preceded vaccination but were diagnosed afterward. Finally, the observational design precludes inference of causality, and temporal association alone cannot establish a direct pathogenic relationship between vaccination and ocular inflammation. This is particularly relevant to the New subgroup, in which diagnoses such as HSV/VZV keratitis and anterior uveitis can occur spontaneously and may be entirely unrelated to vaccination.

In conclusion, ocular inflammation within 30 days of COVID-19 vaccination was uncommon in this large tertiary-center cohort, and corneal allograft rejection was exceptionally rare. These findings support the continued use of COVID-19 vaccination in patients with prior ocular inflammatory disease or corneal transplantation, with appropriate post-vaccination monitoring. Future prospective, population-based studies are needed to better characterize the true incidence of post-vaccination ocular events, identify modifiable risk factors, and establish whether a causal relationship exists between COVID-19 vaccination and specific ocular inflammatory conditions.

Author contributions

SG and SP wrote the main manuscript, handled data analysis, and prepared tables. RH, AP, ASL, and MG were involved with the retrospective review and data collection. EK is the senior and corresponding author, responsible for the following: conceptualization, data management, analysis, manuscript review and revisions.All authors reviewed the manuscript.

Funding

The Bascom Palmer Eye Institute is supported by NIH Center Core Grant P30EY014801 and a Research to Prevent Blindness Unrestricted Grant (GR004596-1).

Data availability

Data will be made available upon reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The requirement for informed consent was waived by the University of Miami Institutional Review Board, as the study involved no prospective patient contact or intervention and posed minimal risk to participants. The study was approved by the University of Miami Institutional Review Board, was conducted in accordance with the principles of the Declaration of Helsinki, and was compliant with the Health Insurance Portability and Accountability Act.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Sadegh Ghafarian and Sarah Pajek contributed equally to this work.

References

  • 1.Yasaka Y, Hasegawa E, Keino H et al (2023) A multicenter study of ocular inflammation after COVID-19 vaccination. Jpn J Ophthalmol 67:14–21. 10.1007/s10384-022-00962-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Huang L-Y, Chiang C-C, Li Y-L et al (2022) Corneal Complications after COVID-19 Vaccination: A Systemic Review. J Clin Med 11:6828. 10.3390/jcm11226828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang MTM, Niederer RL, McGhee CNJ, Danesh-Meyer HV (2022) COVID-19 Vaccination and The Eye. Am J Ophthalmol 240:79–98. 10.1016/j.ajo.2022.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Singh RB, Parmar UPS, Kahale F et al (2023) Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis. Ophthalmology 130:179–186. 10.1016/j.ophtha.2022.08.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hashimoto Y, Yamana H, Iwagami M et al (2023) Ocular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination: Matched Cohort and Self-Controlled Case Series Studies Using a Large Database. Ophthalmology 130:256–264. 10.1016/j.ophtha.2022.10.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pollard AJ, Bijker EM (2021) A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21:83–100. 10.1038/s41577-020-00479-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cheng JY, Margo CE (2022) Ocular adverse events following vaccination: overview and update. Surv Ophthalmol 67:293–306. 10.1016/j.survophthal.2021.04.001 [DOI] [PubMed] [Google Scholar]
  • 8.Biancardi AL, de Moraes HV (2019) Anterior and Intermediate Uveitis Following Yellow Fever Vaccination with Fractional Dose: Case Reports. Ocul Immunol Inflamm 27:521–523. 10.1080/09273948.2018.1510529 [DOI] [PubMed] [Google Scholar]
  • 9.Allen NE, Zhang J, McGhee CNJ (2023) COVID-19 vaccination and corneal allograft rejection- a review. Front Cell Infect Microbiol 13:1307655. 10.3389/fcimb.2023.1307655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu Y-C, Kuo R-L, Shih S-R (2020) COVID-19: The first documented coronavirus pandemic in history. Biomed J 43:328–333. 10.1016/j.bj.2020.04.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Haseeb AA, Solyman O, Abushanab MM et al (2022) Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines (Basel) 10:342. 10.3390/vaccines10020342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hurissi EA, Abuallut II, Dibaji MQ et al (2024) Ocular Complications after COVID-19 Vaccination: A Systematic Review. Med (Kaunas) 60:249. 10.3390/medicina60020249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kim HR, Kim S, Chang MS et al (2024) Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study. Am J Ophthalmol 262:125–133. 10.1016/j.ajo.2024.01.038 [DOI] [PubMed] [Google Scholar]
  • 14.Jordan CA, Townend S, Allen N et al (2023) Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination. Ophthalmology 130:501–508. 10.1016/j.ophtha.2022.12.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nanji AA, Fraunfelder FT (2022) Anterior Uveitis following COVID Vaccination: A Summary of Cases from Global Reporting Systems. Ocul Immunol Inflamm 30:1244–1246. 10.1080/09273948.2022.2042316 [DOI] [PubMed] [Google Scholar]
  • 16.Sim HE, Hwang JH (2023) New onset of acute uveitis following COVID-19 vaccination. Graefes Arch Clin Exp Ophthalmol 261:555–560. 10.1007/s00417-022-05798-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Thorne JE, Suhler E, Skup M et al (2016) Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol 134:1237–1245. 10.1001/jamaophthalmol.2016.3229 [DOI] [PubMed] [Google Scholar]
  • 18.Acharya NR, Tham VM, Esterberg E et al (2013) Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol 131:1405–1412. 10.1001/jamaophthalmol.2013.4237 [DOI] [PubMed] [Google Scholar]
  • 19.Ig GH, Dc W G (2013) Incidence and prevalence of episcleritis and scleritis in Northern California. Cornea 32: 10.1097/ICO.0b013e3182a407c3 [DOI] [PubMed]
  • 20.Cunningham ET, Moorthy RS, Fraunfelder FW, Zierhut M (2019) Vaccine-Associated Uveitis. Ocul Immunol Inflamm 27:517–520. 10.1080/09273948.2019.1626188 [DOI] [PubMed] [Google Scholar]
  • 21.Steinemann TL, Koffler BH, Jennings CD (1988) Corneal allograft rejection following immunization. Am J Ophthalmol 106:575–578. 10.1016/0002-9394(88)90588-0 [DOI] [PubMed] [Google Scholar]
  • 22.Hamad I, Hunter AC, Szebeni J, Moghimi SM (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 46:225–232. 10.1016/j.molimm.2008.08.276 [DOI] [PubMed] [Google Scholar]
  • 23.Zhou Z-H, Stone CA, Jakubovic B et al (2021) Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract 9:1731–1733e3. 10.1016/j.jaip.2020.11.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ibrahim M, Ramadan E, Elsadek NE et al (2022) Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Control Release 351:215–230. 10.1016/j.jconrel.2022.09.031 [DOI] [PubMed] [Google Scholar]
  • 25.Teijaro JR, Farber DL (2021) COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 21:195–197. 10.1038/s41577-021-00526-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Watad A, De Marco G, Mahajna H et al (2021) Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel) 9:435. 10.3390/vaccines9050435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603–2615. 10.1056/NEJMoa2034577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Inagawa S, Onda M, Miyase T et al (2022) Multiple evanescent white dot syndrome following vaccination for COVID-19: A case report. Med (Baltim) 101:e28582. 10.1097/MD.0000000000028582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Orozco LD, Chen H-H, Cox C et al (2020) Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. Cell Rep 30:1246–1259e6. 10.1016/j.celrep.2019.12.082 [DOI] [PubMed] [Google Scholar]
  • 30.Dhir A, Dhir S, Borowski LS et al (2018) Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature 560:238–242. 10.1038/s41586-018-0363-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Farooq AV, Shukla D (2012) Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 57:448–462. 10.1016/j.survophthal.2012.01.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lee TE, Ahn SH, Jeong CY et al (2025) Herpesviral Keratitis Following COVID-19 Vaccination: Analysis of NHIS Database in Korea. Cornea 44:168–179. 10.1097/ICO.0000000000003556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tsatsos M, Prousali E, Karamitsos A, Ziakas N (2025) Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis. Vis (Basel) 9:63. 10.3390/vision9030063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Rallis KI, Fausto R, Ting DSJ et al (2022) Manifestation of Herpetic Eye Disease after COVID-19 Vaccine: A UK Case Series. Ocul Immunol Inflamm 30:1136–1141. 10.1080/09273948.2022.2046795 [DOI] [PubMed] [Google Scholar]
  • 35.Fard AM, Desilets J, Patel S (2022) Recurrence of Herpetic Keratitis after COVID-19 Vaccination: A Report of Two Cases. Case Rep Ophthalmol Med 2022:7094893. 10.1155/2022/7094893 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ryu KJ, Kim DH (2022) Recurrence of Varicella-Zoster Virus Keratitis After SARS-CoV-2 Vaccination. Cornea 41:649–650. 10.1097/ICO.0000000000002999 [DOI] [PubMed] [Google Scholar]
  • 37.Richardson-May J, Rothwell A, Rashid M (2021) Reactivation of herpes simplex keratitis following vaccination for COVID-19. BMJ Case Rep 14:e245792. 10.1136/bcr-2021-245792 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ghafarian S, Samavat B, Lee K et al (2025) Clinical strategies to prevent recurrence of Herpes simplex and Herpes zoster following ocular surgery: A comprehensive review with practical guidelines. Surv Ophthalmol 70:734–755. 10.1016/j.survophthal.2025.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Farrell DA, Deacon S, Mauger T (2022) Marginal keratitis following COVID 19 vaccination. IDCases 29:e01536. 10.1016/j.idcr.2022.e01536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Apivatthakakul A, Goldberg NR, Sobrin L (2023) Birdshot chorioretinopathy in a South Asian patient. Indian J Ophthalmol - Case Rep 3:753. 10.4103/IJO.IJO_2668_22 [DOI] [Google Scholar]
  • 41.Fraunfelder FW, Suhler EB, Fraunfelder FT (2010) Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol 29:26–29. 10.3109/15569520903427717 [DOI] [PubMed] [Google Scholar]
  • 42.Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T et al (2021) UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association. Retina 41:2462–2471. 10.1097/IAE.0000000000003277 [DOI] [PubMed] [Google Scholar]
  • 43.Shah AP, Dzhaber D, Kenyon KR et al (2022) Acute Corneal Transplant Rejection After COVID-19 Vaccination. Cornea 41:121–124. 10.1097/ICO.0000000000002878 [DOI] [PubMed] [Google Scholar]
  • 44.Molero-Senosiain M, Houben I, Savant S, Savant V (2022) Five Cases of Corneal Graft Rejection After Recent COVID-19 Vaccinations and a Review of the Literature. Cornea 41:669–672. 10.1097/ICO.0000000000002980 [DOI] [PubMed] [Google Scholar]
  • 45.Park JM, Lee JH, Hwang JH, Kang M-J (2023) Corneal Graft Rejection after Vaccination against COVID-19: A Case Report. Korean J Ophthalmol 37:85–87. 10.3341/kjo.2022.0105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Singh RB, Li J, Parmar UPS et al (2023) Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. Br J Ophthalmol 108:17–22. 10.1136/bjo-2022-322512 [DOI] [PubMed] [Google Scholar]
  • 47.Zhong Z, Wu Q, Lai Y et al (2022) Risk for uveitis relapse after COVID-19 vaccination. J Autoimmun 133:102925. 10.1016/j.jaut.2022.102925 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Jh JY, Jy K B, et al (2021) Effects of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine. Frontiers in immunology 12: 10.3389/fimmu.2021.744206 [DOI] [PMC free article] [PubMed]
  • 49.Eissa M, Abdelrazek NA, Saady M (2023) Covid-19 and its relation to the human eye: transmission, infection, and ocular manifestations. Graefes Arch Clin Exp Ophthalmol 261:1771–1780. 10.1007/s00417-022-05954-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yeo S, Kim H, Lee J et al (2023) Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review. Graefes Arch Clin Exp Ophthalmol 261:1793–1808. 10.1007/s00417-022-05953-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Kim J, Ahn SJ (2024) Risk of Post-COVID-19 Uveitis and Risk Modification by Vaccination: A Nationwide Retrospective Cohort Study. Vaccines (Basel) 12:631. 10.3390/vaccines12060631 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Sanjay S, Kundu G, Deshpande V et al (2023) Coronavirus disease 19 (COVID-19) and viral keratouveitis - unraveling the mystery. Indian J Ophthalmol 71:3103–3108. 10.4103/IJO.IJO_593_23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Koo EH, Eghrari AO, Dzhaber D et al (2021) Presence of SARS-CoV-2 Viral RNA in Aqueous Humor of Asymptomatic Individuals. Am J Ophthalmol 230:151–155. 10.1016/j.ajo.2021.05.008 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data will be made available upon reasonable request.


Articles from Journal of Ophthalmic Inflammation and Infection are provided here courtesy of Springer-Verlag

RESOURCES